3-hydroxyisothiazole 1-oxide derivatives
AssigneeMochida Pharmaceutical Co., Ltd.
InventorMunetaka Ohkouchi
Life of this patent
Estimating the term…
Abstract
[Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
Claims15
A compound of Formula (II)-4a:
- wherein p is an integer of 0 to 4;
- R1s are independently a group arbitrarily selected from a halogen atom, a C1-6 alkyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C2-6 alkenyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C2-6 alkynyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C1-6 alkoxy group which is optionally substituted with 1 to 5 substituent(s) RI and a cyano group;
- R2 is a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group or a cyano group;
- q is an integer of 0 to 4;
- s is an integer of 0 to 2;
- q1 is an integer of 0 to 3;
- r1 is an integer of 0 to 2;
- a ring A′ is an aryl group or a heteroaryl group;
- V is a single bond or an oxygen atom;
- R8s are independently a group arbitrarily selected from a C1-6 alkoxy group which is substituted with 1 to 5 substituent(s) RIII, an aralkyloxy group, a heterocyclic oxy group (the heterocyclic oxo group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s)) or a heterocyclic group (the heterocyclic group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s));
- the substituent RIII is a group arbitrarily selected from —OH, a C1-6 alkoxy group, an aryl group (the aryl group is optionally and arbitrarily substituted with 1 to 3 halogen atom(s)), a heterocyclic group (the heterocyclic group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s)), a group:
- —S(O)iRa (i is an integer of 0 to 2), a group:
- —SO2NRdRe, a group:
- —CONRdRe and a group:
- —NRb1Rc1;
- R9s are independently a group arbitrarily selected from a halogen atom, a cyano group, a C1-6 alkyl group (the C1-6 alkyl group is optionally and arbitrarily substituted with 1 to 5 halogen atom(s), 1 to 5 —OH or 1 to 5 C1-6 alkoxy group(s)), a C1-6 alkoxy group (the C1-6 alkoxy group is optionally and arbitrarily substituted with 1 to 5 halogen atom(s)), a C2-6 alkenyl group, a C2-7 alkanoyl group, a group:
- —S(O)iRa(i is an integer of 0 to 2), a group:
- —CONRdRe and a group:
- —NRb1Rc1;
- R11 and R12 are independently a halogen atom, —OH, a cyano group, a C1-6 alkyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C2-6 alkenyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C2-6 alkynyl group which is optionally substituted with 1 to 5 substituent(s) RI, a C1-6 alkoxy group which is optionally substituted with 1 to 5 substituent(s) RI, —SH, a group:
- —S(O)iRa (i is an integer of 0 to 2), or a group:
- —NRbRc;
- Ra is a group arbitrarily selected from a C1-6 alkyl group and a halogenated C1-6 alkyl group;
- Rb and Rc are independently a group arbitrarily selected from a hydrogen atom, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C2-7 alkanoyl group (the alkanoyl group is optionally substituted with —OH or a C1-6 alkoxy group), a C1-6 alkylsulfonyl group, an arylcarbonyl group and a heterocyclic carbonyl group, or Rb and Rc optionally form together with a nitrogen atom to which Rb and Rc are bonded, a 3- to 8-membered cyclic group, where in the cyclic group, one or two carbon atom(s) is(are) optionally substituted with an atom arbitrarily selected from an oxygen atom, a sulfur atom, and a nitrogen atom (the nitrogen atom is optionally substituted with a C1-6 alkyl group which is optionally substituted with 1 to 5 substituent(s) RI) or with a carbonyl group, and the cyclic group is optionally further substituted with 1 to 5 substituent(s) RII;
- the above-mentioned substituents RI are the same as or different from each other and are each a group arbitrarily selected from a halogen atom, —OH, a cyano group, a C1-6 alkoxy group (the C1-6 alkoxy group is optionally substituted with 1 to 5 halogen atom(s), 1 to 5 —OH, 1 to 5 C1-6 alkoxy group(s), 1 to 5 aryl group(s) (the aryl group is optionally and arbitrarily substituted with 1 to 3 halogen atom(s)), 1 to 5 heterocyclic group(s) (the heterocyclic group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s)), 1 to 5 group(s):
- —S(O)iRa (i is an integer of 0 to 2), 1 to 5 group(s):
- —SO2NRdRe, 1 to 5 group(s):
- —CONRdRe or 1 to 5 group(s):
- —NRb1Rc1), a group:
- —NRb1Rc1 and a heterocyclic oxy group (the heterocyclic oxy group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s));
- the above-mentioned substituents RII are the same as or different from each other and are each a group arbitrarily selected from the above-mentioned substituent RI, a C1-6 alkyl group (the C1-6 alkyl group is optionally and arbitrarily substituted with 1 to 5 halogen atom(s), 1 to 5 —OH, 1 to 5 C1-6 alkoxy group(s), 1 to 5 group(s):
- —S(O)iRa (i is an integer of 0 to 2), 1 to 5 group(s):
- —SO2NRdRe, 1 to 5 group(s):
- —CONRdRe or 1 to 5 group(s):
- —NRb1Rc1), a C2-6 alkenyl group, a C2-7 alkanoyl group, an aralkyloxy group, a heterocyclic group (the heterocyclic group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s)), a heterocyclic carbonyl group (the heterocyclic carbonyl group is optionally and arbitrarily substituted with 1 to 3 C1-6 alkyl group(s) or 1 to 3 oxo group(s)), a group:
- —S(O)iRa (i is an integer of 0 to 2), a group:
- —CONRdRe, and a group:
- —CONRdRe1;
- Rd and Re are independently a hydrogen atom or a C1-6 alkyl group (the C1-6 alkyl group is optionally substituted with 1 to 5 halogen atom(s), 1 to 5 —OH or 1 to 5 C1-6 alkoxyl group(s));
- Rel is a C1-6 alkyl group (the C1-6 alkyl group is optionally substituted with 1 to 5 —OH, 1 to 5 C1-6 alkoxyl group(s), 1 to 5 aryl group(s) (the aryl group is optionally substituted with 1 to 3 halogen atom(s)), 1 to 5 heterocyclic group(s) (the heterocyclic group is optionally substituted with 1 to 3 C1-6 alkyl group or 1 to 3 oxo group(s)), 1 to 5 —S(O)iRa group(s) (i is an integer of 0 to 2), 1 to 5 —SO2NRdRe group(s), 1 to 5 —CONRdRe group(s) or 1 to 5 —NRb1Rc1 group(s);
- Rb1 and Rc1 are independently a group arbitrarily selected from a hydrogen atom, a C1-6 alkyl group, a C2-7 alkanoyl group and a C1-6 alkylsulfonyl group, or Rb1 and Rc1 optionally form together with a nitrogen atom to which Rb1 and Rc1 are bonded, a 3- to 8-membered cyclic group, where in the cyclic group, one or two carbon atom(s) is(are) optionally substituted with an atom arbitrarily selected from an oxygen atom, a sulfur atom, and a nitrogen atom (the nitrogen atom is optionally substituted with a C1-6 alkyl group) or with a carbonyl group;
- or a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the salt or a pharmaceutically acceptable solvate of the compound.
A compound selected from:
- 6) 3-hydroxy-5-(4-((7-phenoxy-2,3-dihydrobenzofuran-3-yl)oxy)phenyl)isothiazole 1-oxide;
- 7) 3-hydroxy-5-(4-((7-((6-methoxypyridin-3-yl)oxy)-2,3-dihydrobenzofuran-3-yl)oxy)phenyl)isothiazole 1-oxide;
- 8) 3-hydroxy-5-(4-((7-((6-(3-hydroxy-3-methylbutoxy)-2-methylpyridin-3-yl)oxy)-2,3-dihydrobenzofuran-3-yl)oxy)phenyl)isothiazole 1-oxide;
- 9) 3-hydroxy-5-(4-((7-((6-(3-hydroxy-3-methylbutoxy)-2-methylpyridin-3-yl)-2,3-dihydrobenzofuran-3-yl)oxy)phenyl)isothiazole 1-oxide;
- 10) 3-hydroxy-5-(4-((7-(4-(3-hydroxy-3-methylbutoxy)-2,6-dimethylphenyl)-2,3-dihydrobenzofuran-3-yl)oxy)phenyl)isothiazole 1-oxide;
- or a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the salt or a pharmaceutically acceptable solvate of the compound, and optical isomers of the compounds, or a pharmaceutically acceptable salt of the optical isomer, or a pharmaceutically acceptable solvate of the salt or a pharmaceutically acceptable solvate of the optical isomer.
Dependencies are inferred from the claim text.